Entrada Therapeutics (TRDA) News Today → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free TRDA Stock Alerts $13.38 +0.28 (+2.14%) (As of 11:33 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineFriday 4/12 Insider Buying Report: ATOS, TRDAnasdaq.com - April 14 at 3:12 PMInsiders are Piling into These 5 Healthcare Stocks in 2024insidermonkey.com - April 12 at 12:03 AMInsiders Buying America's Car-Mart And 2 Other Stocksmsn.com - April 11 at 7:02 PMEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 2,600 Sharesinsidertrades.com - April 11 at 6:48 AMPeter S. Kim Buys 2,600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stockmarketbeat.com - April 10 at 6:42 PMPeter S. Kim Acquires 1,512 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stockinsidertrades.com - April 2 at 4:26 AMEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Buys $20,790.00 in Stockmarketbeat.com - April 1 at 6:47 PMDirector Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)finance.yahoo.com - March 27 at 10:44 AMPeter S. Kim Acquires 3,180 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stockinsidertrades.com - March 27 at 5:26 AMEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Buys $42,484.80 in Stockmarketbeat.com - March 26 at 6:42 PMInsider Buying: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Purchases 900 Shares of Stockinsidertrades.com - March 22 at 11:12 AMEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 900 Sharesmarketbeat.com - March 21 at 7:58 PMEntrada Therapeutics, Inc. (NASDAQ:TRDA) to Post Q1 2024 Earnings of ($0.40) Per Share, HC Wainwright Forecastsmarketbeat.com - March 20 at 5:45 AMEntrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimatesfinance.yahoo.com - March 19 at 9:52 AMHC Wainwright Reaffirms "Buy" Rating for Entrada Therapeutics (NASDAQ:TRDA)marketbeat.com - March 18 at 5:32 PMEntrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical Pipelinemarkets.businessinsider.com - March 18 at 1:40 PMEquities Analysts Offer Predictions for Entrada Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TRDA)marketbeat.com - March 18 at 1:27 AMTD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)markets.businessinsider.com - March 13 at 8:49 PMEntrada Therapeutics, Inc.: Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Resultsfinanznachrichten.de - March 13 at 10:48 AMRecap: Entrada Therapeutics Q4 Earningsbenzinga.com - March 13 at 10:48 AMEntrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 13 at 7:00 AMEntrada Therapeutics Stock (NASDAQ:TRDA) Insider Tradesbenzinga.com - February 23 at 2:23 AM‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocksfinance.yahoo.com - January 29 at 8:27 AMEntrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Sells $15,990.00 in Stockmarketbeat.com - January 18 at 7:24 PMAmicus (FOLD) Issues Preliminary Revenue Results for FY23finance.yahoo.com - January 8 at 11:58 AMOppenheimer Initiates Coverage of Entrada Therapeutics (TRDA) with Outperform Recommendationmsn.com - January 6 at 8:22 AMEntrada Therapeutics (NASDAQ:TRDA) Now Covered by Oppenheimermarketbeat.com - January 5 at 8:11 AMBEAM Stock Rallies More Than 25% in 3 Months: What Next?finance.yahoo.com - January 3 at 1:30 PMEntrada Therapeutics Promotes Nathan J. Dowden to Presidentfinance.yahoo.com - January 3 at 8:30 AMEntrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Sharesfinance.yahoo.com - December 28 at 9:29 AMKory James Wentworth Sells 10,206 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stockmarketbeat.com - December 26 at 6:41 PMEntrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Dipal Doshi Sells 1,000 Sharesmarketbeat.com - December 22 at 6:52 PMAnavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAAfinance.yahoo.com - December 20 at 1:05 PMRoche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tagfinance.yahoo.com - December 20 at 1:05 PMEntrada Therapeutics Stock (NASDAQ:TRDA) Dividends: History, Yield and Datesbenzinga.com - December 11 at 1:30 PMPfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EUfinance.yahoo.com - December 11 at 1:30 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDAbenzinga.com - November 29 at 6:46 PMImmunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Datafinance.yahoo.com - November 29 at 1:45 PMHC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Knowmarkets.businessinsider.com - November 27 at 1:40 PMEntrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drugfinance.yahoo.com - November 23 at 5:02 PMBiotech Stock Roundup: BMY, TSVT Down on Setback, TRDA, MOR Offer Updatesfinance.yahoo.com - November 23 at 12:01 PMPositive Prospects for Entrada Therapeutics Despite FDA Hold: An Analyst’s Buy Rating Justificationmarkets.businessinsider.com - November 23 at 7:00 AMEntrada shares slide as FDA maintains freeze on Duchenne drugbizjournals.com - November 22 at 5:01 PMWhy Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today?markets.businessinsider.com - November 22 at 5:01 PMEntrada Therapeutics Shares Tumble 27% After FDA Keeps Clinical Holdmarketwatch.com - November 22 at 12:00 PMEntrada Therapeutics Says FDA Declines To Lift Clinical Hold On ENTR-601-44 IND Applicationmarkets.businessinsider.com - November 22 at 12:00 PMEntrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophyfinance.yahoo.com - November 22 at 12:00 PMEntrada Therapeutics’ Promising Phase 1 Trial and Broad Tissue Distribution Profile Underpin Buy Ratingmarkets.businessinsider.com - November 9 at 10:49 AMNew Forecasts: Here's What Analysts Think The Future Holds For Entrada Therapeutics, Inc. (NASDAQ:TRDA)finance.yahoo.com - November 9 at 10:49 AMEntrada Therapeutics Inc TRDAmorningstar.com - November 8 at 6:18 PM Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about... Click here to see Louis' new video for yourself. TRDA Media Mentions By Week TRDA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRDA News Sentiment▼0.000.46▲Average Medical News Sentiment TRDA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRDA Articles This Week▼01▲TRDA Articles Average Week Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Biomea Fusion News Harrow Health News Lexicon Pharmaceuticals News Heron Therapeutics News PepGen News Neurogene News Mersana Therapeutics News Revance Therapeutics News Avid Bioservices News Fulcrum Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRDA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
